AU2022341188A1 - Prevention of respiratory syncytial virus lower respiratory tract infection with nirsevimab - Google Patents

Prevention of respiratory syncytial virus lower respiratory tract infection with nirsevimab Download PDF

Info

Publication number
AU2022341188A1
AU2022341188A1 AU2022341188A AU2022341188A AU2022341188A1 AU 2022341188 A1 AU2022341188 A1 AU 2022341188A1 AU 2022341188 A AU2022341188 A AU 2022341188A AU 2022341188 A AU2022341188 A AU 2022341188A AU 2022341188 A1 AU2022341188 A1 AU 2022341188A1
Authority
AU
Australia
Prior art keywords
rsv
nirsevimab
subject
dose
season
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022341188A
Other languages
English (en)
Inventor
Mark Thomas ESSER
Amanda LEACH
Tonya Luana VILLAFANA
Deidre Elaine WILKINS
Ulrika WÄHLBY HAMRÉN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
SANOFI PASTEUR Inc
Original Assignee
MedImmune Ltd
SANOFI PASTEUR Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd, SANOFI PASTEUR Inc filed Critical MedImmune Ltd
Publication of AU2022341188A1 publication Critical patent/AU2022341188A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
AU2022341188A 2021-09-13 2022-09-12 Prevention of respiratory syncytial virus lower respiratory tract infection with nirsevimab Pending AU2022341188A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163261117P 2021-09-13 2021-09-13
US63/261,117 2021-09-13
US202263266594P 2022-01-10 2022-01-10
US63/266,594 2022-01-10
US202263363633P 2022-04-26 2022-04-26
US63/363,633 2022-04-26
US202263364554P 2022-05-11 2022-05-11
US63/364,554 2022-05-11
PCT/US2022/076311 WO2023039584A2 (en) 2021-09-13 2022-09-12 Prevention of respiratory syncytial virus lower respiratory tract infection with nirsevimab

Publications (1)

Publication Number Publication Date
AU2022341188A1 true AU2022341188A1 (en) 2024-03-14

Family

ID=83508746

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022341188A Pending AU2022341188A1 (en) 2021-09-13 2022-09-12 Prevention of respiratory syncytial virus lower respiratory tract infection with nirsevimab

Country Status (9)

Country Link
US (1) US20250340622A1 (cg-RX-API-DMAC7.html)
EP (1) EP4402166A2 (cg-RX-API-DMAC7.html)
JP (1) JP2024535009A (cg-RX-API-DMAC7.html)
KR (1) KR20240055097A (cg-RX-API-DMAC7.html)
AU (1) AU2022341188A1 (cg-RX-API-DMAC7.html)
CA (1) CA3229901A1 (cg-RX-API-DMAC7.html)
IL (1) IL310974A (cg-RX-API-DMAC7.html)
TW (1) TW202340237A (cg-RX-API-DMAC7.html)
WO (1) WO2023039584A2 (cg-RX-API-DMAC7.html)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS60387B1 (sr) 2014-01-15 2020-07-31 Medimmune Llc Rsv-specifična antitela i njihovi funkcionalni delovi
US12024553B2 (en) * 2019-04-30 2024-07-02 Medimmune Limited Dosage regimens for and compositions including anti-RSV antibodies

Also Published As

Publication number Publication date
WO2023039584A2 (en) 2023-03-16
KR20240055097A (ko) 2024-04-26
WO2023039584A3 (en) 2023-04-06
CA3229901A1 (en) 2023-03-16
IL310974A (en) 2024-04-01
US20250340622A1 (en) 2025-11-06
EP4402166A2 (en) 2024-07-24
JP2024535009A (ja) 2024-09-26
TW202340237A (zh) 2023-10-16

Similar Documents

Publication Publication Date Title
Fenton et al. Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection
US12565526B2 (en) Formulations of anti-RSV antibodies and methods of use thereof
JP7851613B2 (ja) 抗SARS-CoV-2スパイク糖タンパク質抗体を用いてSARS-CoV-2感染及びCOVID-19を治療又は予防するための方法
TWI861099B (zh) 包含抗rsv抗體之組合物及劑量方案
CN117980333A (zh) 用st2拮抗剂治疗慢性阻塞性肺疾病的方法
TWI454279B (zh) 抗單純皰疹病毒抗體及其使用方法
US20250042985A1 (en) Interleukin 5 binding protein dosage regimen for use in treating polyangiitis, hypereosinophilic syndrome, chronic rhinosinusitis with nasal polyps (crswnp), or chronic rhinosinusitis without nasal polyps (crssnp)
de Toledo et al. Antiviral therapies for respiratory syncytial virus infection: current expectations
EP4267184B1 (en) Interleukin 5 binding protein dosage regimen
US20250340622A1 (en) Prevention of respiratory syncytial virus lower respiratory tract infection with nirsevimab
WO2021260692A1 (en) Compositions and methods for treating infectious disease caused by coronavirus
EA053309B1 (ru) Предупреждение инфекции нижнего респираторного тракта, вызываемой респираторно-синцитиальным вирусом, с помощью нирсевимаба
CN118302441A (zh) 尼塞韦单抗预防呼吸道合胞病毒下呼吸道感染
WO2021207697A1 (en) Treatment of acute lung injury
CA3115708C (en) Formulations of anti-rsv antibodies and methods of use thereof
WO2025235420A1 (en) Methods of treating or preventing sarbecovirus with antibodies or antigen-binding fragments thereof
KR20220010411A (ko) 사스-코로나바이러스 감염증을 예방 또는 치료하기 위한 투여 요법
KR20220010456A (ko) 사스-코로나바이러스 감염증을 예방 또는 치료하기 위한 투여 요법
TW202613166A (zh) 黏液栓塞的治療
KR20220010410A (ko) 사스-코로나바이러스 감염증을 예방 또는 치료하기 위한 투여 요법
WO2026080293A1 (en) Anti-human rsv f protein antibodies for use in treatment or prophylaxis
WO2023081434A2 (en) Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies
EA050682B1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ИНФЕКЦИЙ SARS-CoV-2 И COVID-19 С ПРИМЕНЕНИЕМ АНТИТЕЛ К ШИПОВИДНОМУ ГЛИКОПРОТЕИНУ SARS-CoV-2
KR20220010402A (ko) 사스-코로나바이러스 감염증을 예방 또는 치료하기 위한 투여 요법